Novavax vaccine recommended for approval for EU teenagers

A positive recommendation from the EU committee CHMP concerning the use of the Novavax vaccine in teenagers has turned Novavax’s stock fortunes upside down after months of losses.
by marketwire, translated by catherine brett

Shares in US-based vaccine producer Novovax increased in value by 13.9% on Thursday in US trading after the Committee for Medicinal Products for Human Use, the CHMP, recommended the vaccine be used in children aged 12-17.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading